MODIFICATION TO VYSIS UROVYSION BLADDER CANCER RECURRENCE TEST— 510(k) K033982
Substantially EquivalentVysis
FDA 510(k) clearance K033982 for MODIFICATION TO VYSIS UROVYSION BLADDER CANCER RECURRENCE TEST, Substantially Equivalent on 2004-01-22. Applicant: Vysis. Device class: 2.
Clearance details
- Applicant
- Vysis
- Product code
- Code MMW
- Device class
- Class 2
- Regulation
- 21 CFR 866.6010
- Advisory panel
- Immunology
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Special
- Location
- Downers Grove, IL, US
Recent devices under product code MMW
view all- K203245 — Bladder EpiCheck DNA extraction kit, NX899090-01C, Bladder EpiCheck test kit, NX899090-02C, Bladder EpiCheck Software, NX899090-03C
- K021231 — NMP22 BLADDERCHEK KIT, NMP22 CONTROL KIT
- K013785 — UROVYSION BLADDER CANCER RECURRENCE KIT
- K011031 — VYSIS UROVYSION BLADDER CANCER RECURRENCE KIT
- K974845 — BTA STAT TEST PRESCRIPTION HOME USE
More clearances from Vysis
view allData sourced from openFDA. This site is unofficial and independent of the FDA.